Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Miloš Milojković"'
Autor:
Lidija Ristić, Milan Rančić, Milan Radović, Dane Krtinić, Milorad Pavlović, Bojan Ilić, Miloš Milojković, Nikola Živković, Ksenija Turković, Dušan Sokolović
Publikováno v:
Archives of Medical Science, Vol 20, Iss 3, Pp 977-983 (2020)
Introduction Cisplatin is one of the most frequently used chemotherapeutics, which is known to cause both tumor and normal lung tissue damage through the generation of free radicals and cells apoptosis/necrosis. Melatonin is a neurohormone that regul
Externí odkaz:
https://doaj.org/article/6339dc6b7e6f4767903d46078567657c
Autor:
Dane Krtinić, Nikola Živković, Dušan Sokolović, Lidija Ristic, Miloš Milojković, Bojan Ilić, Andrija Rančić, Milan Rancic, Milorad Pavlovic
Publikováno v:
Pharmacology. 106:400-408
Introduction: Antioxidants such as lycopene (LCP) and caffeic acid phenethyl ester (CAPE) represent ideal molecules for the treatment of different reactive oxygen species (ROS) associated disorders. Cisplatin is a chemotherapeutic agent, causing an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32b8236bcdce64b73723d4958a25281
https://doi.org/10.1159/000515935
https://doi.org/10.1159/000515935
Autor:
Milan Rancic, Dušan Sokolović, Ksenija Turković, Dane Krtinić, Milan Radovic, Miloš Milojković, Milorad Pavlovic, Bojan Ilić, Lidija Ristic, Nikola Živković
Publikováno v:
Archives of Medical Science.
IntroductionCisplatin is one of the most frequently used chemotherapeutics, which is known to cause both tumor and normal lung tissue damage through the generation of free radicals and cells apoptosis/necrosis. Melatonin is a neurohormone that regula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e7316c0696696cb05398cd8cce152a9
https://doi.org/10.5114/aoms.2020.95952
https://doi.org/10.5114/aoms.2020.95952
Autor:
Milorad Pavlovic, Senada Pavlović, Bojan Ilić, Desa Nastasijević Borovac, Dušica Ilić, Miloš Milojković, Milos S. Stankovic
Publikováno v:
Acta Medica Medianae. 57:101-105
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da5e60e727b8e2f951526151d78b5707
https://doi.org/10.5633/amm.2018.0216
https://doi.org/10.5633/amm.2018.0216
Publikováno v:
Thoracic surgery.
Benefits of 5-year survivals after pulmonary metastasectomy of colorectal carcinoma range from 21% - 62%. Selection criteria were completely resectable lesions in the lung, lesions 36 months = 24, 31%. Median DFI = 29.3 months (0-79 m.). Single metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b62e2dfdad54bcf42148c90f1324ac23
https://doi.org/10.1183/13993003.congress-2019.pa1095
https://doi.org/10.1183/13993003.congress-2019.pa1095